Assenagon Asset Management S.A. trimmed its stake in shares of Accuray Incorporated (NASDAQ:ARAY) by 79.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,000 shares of the medical equipment provider’s stock after selling 287,851 shares during the period. Assenagon Asset Management S.A.’s holdings in Accuray were worth $152,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently bought and sold shares of the company. HighTower Advisors LLC purchased a new position in Accuray during the first quarter valued at $29,000. US Bancorp DE lifted its holdings in Accuray by 950.0% during the first quarter. US Bancorp DE now owns 15,750 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 14,250 shares in the last quarter. Diversified Trust Co purchased a new position in Accuray during the second quarter valued at $31,000. Mackenzie Financial Corp purchased a new position in Accuray during the first quarter valued at $40,000. Finally, Royal Bank of Canada lifted its holdings in Accuray by 619,575.0% during the first quarter. Royal Bank of Canada now owns 24,787 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 24,783 shares in the last quarter. 72.19% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts have issued reports on ARAY shares. Cowen reaffirmed an “average” rating and set a $8.00 price objective on shares of Accuray in a report on Sunday, June 21st. BTIG Research reissued a “buy” rating and issued a $6.00 price target on shares of Accuray in a research note on Wednesday, June 17th. ValuEngine raised shares of Accuray from a “hold” rating to a “buy” rating in a research note on Friday, May 1st. Finally, Lake Street Capital reissued a “buy” rating and issued a $10.00 price target on shares of Accuray in a research note on Sunday, June 21st. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. Accuray has a consensus rating of “Hold” and an average price target of $7.00.
NASDAQ:ARAY opened at $2.23 on Friday. The company’s 50-day moving average price is $2.19 and its 200-day moving average price is $2.44. The company has a current ratio of 1.95, a quick ratio of 1.20 and a debt-to-equity ratio of 3.62. The company has a market cap of $201.86 million, a P/E ratio of 111.56 and a beta of 2.03. Accuray Incorporated has a twelve month low of $1.33 and a twelve month high of $4.68.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Read More: Cryptocurrencies
Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Incorporated (NASDAQ:ARAY).
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.